| Literature DB >> 14574034 |
Gerald V Naccarelli1, Deborah L Wolbrette, Luna Bhatta, Mazhar Khan, John Hynes, Soraya Samii, Jerry Luck.
Abstract
Clinical trials assessing the efficacy of anti- arrhythmic drugs for terminating atrial fibrillation have demonstrated that rate control drugs have little to no added efficacy compared to placebo; however, spontaneous conversion of recent-onset atrial fibrillation is common. Antiarrhythmic drugs such as oral dofetilide, oral bolus-flecainide and propafenone and intravenous ibutilide all have a role in terminating atrial fibrillation. Active comparator trials have demonstrated that amiodarone is more efficacious in maintaining sinus rhythm than propafenone and sotalol. Multiple trials have demonstrated the safety of amiodarone, sotalol, dofetilide and azimilide in a post-myocardial infarction population and amiodarone and dofetilide in a congestive heart failure population. Newer antiarrhythmic agents, some with novel mechanisms of action, will add to the pharmacologic armamentarium in treating atrial fibrillation.Entities:
Mesh：
Substances：
Year: 2003 PMID： 14574034 DOI： 10.1023/a:1026240625182
Source DB: PubMed Journal: J Interv Card Electrophysiol ISSN： 1383-875X Impact factor: 1.900